Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.55 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | ADK | P55263 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | MMP2 | P08253 | 4/20 | 0.50 |
| ▸ | MMP9 | P14780 | 4/20 | 0.50 |
| ▸ | MMP8 | P22894 | 4/20 | 0.50 |
| ▸ | MMP13 | P45452 | 3/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluorene SCHEMBL28814858 | 0.85 | NISCH (0.46) | NPC1RAB9AMEN1HSP90AA1AGTR1 | |
| Hydrochloric Acid SCHEMBL11731414 | 0.82 | MAPT (0.48) | NPC1RAB9AMEN1HSP90AA1AGTR1 | |
| SCHEMBL722191 | 0.80 | NISCH (0.78) | MEN1KMT2ANISCHMTORADK | |
| SCHEMBL1655585 | 0.80 | MAPT (0.56) | NPC1RAB9AMEN1KMT2ANISCH | |
| SCHEMBL4858552 | 0.78 | KMT2A (0.48) | NPC1RAB9AMEN1HSP90AA1AGTR1 | |
| SCHEMBL862114 | 0.78 | NISCH (0.75) | MEN1KMT2ANISCHMTORADK | |
| SCHEMBL11363412 | 0.78 | MAPT (0.43) | NPC1RAB9AMEN1HSP90AA1AGTR1 | |
| 2-Phenylimidazole SCHEMBL28960135 | 0.77 | NISCH (0.72) | NPC1RAB9AMEN1KMT2ANISCH | |
| SCHEMBL8539529 | 0.77 | GPR35 (0.49) | NPC1RAB9AMEN1HSP90AA1AGTR1 | |
| SCHEMBL5249670 | 0.77 | MAPT (0.56) | NPC1RAB9AMEN1HSP90AA1AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105705656-B | Method of producing a composite material | 牛津纳米孔技术公司 | 2020-02-21 | — | — | CN | claimed |
| CN-101863894-B | Tanshinone II A derivative and preparation method and application thereof | UNIV GUANGDONG PHARM | 2012-07-18 | — | — | CN | claimed |
| CN-101863894-A | Tanshinone II A derivative and preparation method and application thereof | GUANGDONG PHARMACEUTICAL UNIVERSITY | 2010-10-20 | — | — | CN | claimed |
| CN-101735217-A | Application of imidazole [4,5-f][1,10] phenanthroline and derivative thereof to preparation of antineoplastic drug | UNIV GUANGDONG PHARM | 2010-06-16 | — | — | CN | claimed |
| EP-1448793-B1 | ANNEALING CONTROL PRIMER AND ITS USES | SEEGENE INC (KR) | 2008-09-03 | — | — | EP | claimed |
| EP-0365907-B1 | Process for the preparation of p-nitrophenyl imidazoles | BASF AG (DE) | 1993-12-22 | — | — | EP | claimed |
| US-5008398-A | Preparation of p-nitrophenyl-imidazoles | BASF AKTIENGESELLSCHAFT (DE) | 1991-04-16 | — | — | US | claimed |
| EP-0365907-A1 | Process for the preparation of p-nitrophenyl imidazoles | BASF Aktiengesellschaft (DE) | 1990-05-02 | — | — | EP | claimed |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-12 | — | — | US | disclosed |
| US-12187720-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-07 | — | — | US | disclosed |
| US-11465987-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc. (US) | 2022-01-27 | — | — | US | disclosed |
| EP-3020717-B1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO (JP) | 2021-12-15 | — | — | EP | disclosed |
| US-11084811-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2021-08-10 | — | — | US | disclosed |
| US-4956470-A | BACTERICIDES, FUNGICIDES, ANTHELMINTICS, ANTIPROTOZOA AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1990-09-11 | — | — | US | disclosed |
| EP-0365907-A1 | Process for the preparation of p-nitrophenyl imidazoles | BASF Aktiengesellschaft (DE) | 1990-05-02 | — | — | EP | disclosed |
| EP-0365907-A1 | Process for the preparation of p-nitrophenyl imidazoles | BASF Aktiengesellschaft (DE) | 1990-05-02 | — | — | EP | disclosed |
| US-4814332-A | PARASITICIDES | HOFFMAN-LA ROCHE INC. (US) | 1989-03-21 | — | — | US | disclosed |
| EP-0306440-A2 | 1-(4-substituted phenyl)-1H-imidazoles as cardiovascular agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-03-08 | — | — | EP | disclosed |
| EP-0253084-A2 | 1,3-Disubstituted imidazolium salts | F. HOFFMANN-LA ROCHE AG (CH) | 1988-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187720-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | NPC1 1453/4885RAB9A 1147/4885MEN1 165/4885 |
| US-11084811-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | NPC1 1453/4885RAB9A 1147/4885MEN1 165/4885 |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | NPC1 1453/4885RAB9A 1147/4885MEN1 165/4885 |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | NPC1 1453/4885RAB9A 1147/4885MEN1 165/4885 |
| US-11465987-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | NPC1 1453/4885RAB9A 1147/4885MEN1 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.